arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Ernexa Therapeutics Inc.

ERNA
$4.41 ▼ -0.09 (-2.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
32 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Ernexa Therapeutics Inc. shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $3.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -80.9%
FCF / Share $-2.86
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.00K
↓ -94.1%
Net Income Profit after all expenses
$-5.51M
↑ +32.9%
Operating Margin Operating profit as % of sales
-463.9%
↓ -383.2%
FCF / Share Free cash flow per share
$-2.86
↓ -7293.3%
Long-Term Debt Long-term obligations
$725.00K
↓ -55.4%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -386.9% is weak on an absolute basis (target > 10%)
  • Interest CoverageInterest Coverage of -423.59x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.50x is weak on an absolute basis (target > 1x)

Health Breakdown

Financial Health
18
Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters